论文部分内容阅读
非风湿性心房颤动患者具有并发栓塞性中风和其它体循环栓塞的高度危险,SPAF试验(Stroke Prevention in Atrial Fibrillation Trial)是应用华法令和阿斯匹林预防房颤并发体循环栓塞的大规模临床试验之一。 SPAF将非风湿性房颤病人按是否适合华法令治疗分为二组。组1适合华法令治疗的627例随机平分为公开的华法令治疗组与双盲的阿斯匹林治疗组或配对的安慰剂组。组2不适合华法令治疗的703例,随机分为双盲的阿斯匹林组或配对的安慰剂组。华法令用量平均每日4.8mg,治疗指标是使凝血酶原时间延长
Patients with non-rheumatic atrial fibrillation have a high risk of concurrent thromboembolic stroke and other systemic embolisms. The SPAF trial (Stroke Prevention in Atrial Fibrillation Trial) is a large-scale clinical trial using warfarin and aspirin to prevent atrial fibrillation complicated by systemic embolism one. SPAF will be non-rheumatic atrial fibrillation patients are eligible for warfarin treatment is divided into two groups. Group 1 627 patients eligible for warfarin were randomized equally to either warfarin-treated and double-blind aspirin-treated or matched placebo. Group 2 Not suitable for warfarin treatment of 703 cases were randomly divided into double-blind aspirin group or matched placebo group. The average daily dosage of warfarin is 4.8mg, and the therapeutic index is to prolong the prothrombin time